| Literature DB >> 10654451 |
A Keyhani1, Y O Huh, D Jendiroba, L Pagliaro, J Cortez, S Pierce, M Pearlman, E Estey, H Kantarjian, E J Freireich.
Abstract
CD38 is expressed in acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) blasts and its prognostic significance is unknown. We investigated CD38 expression in 304 AML and 138 ALL patients. CD38 was lower in AML-M3 compared to other FAB subtypes (5% vs. 41%; P < 0.001), but was similar among ALL subtypes (56.6%; P = 0.69). Ph + ALL and AML with t(15; 17) patients showed lower CD38 expression than the other cytogenetic groups. Overall survival favored AML and ALL patients with higher CD38 levels. Multivariate analysis revealed CD38 expression to be an independent outcome predictor in AML, but not in ALL.Entities:
Mesh：
Substances：
Year: 2000 PMID： 10654451 DOI： 10.1016/s0145-2126(99)00147-2
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156